PolyPid Third Quarter 2026 Conference Call - POLYPID LTD

Financial Performance:

• Net loss for Q3 2026 narrowed to $5.8 million ($0.24/share) from $7.5 million ($0.37/share) in Q3 2025; nine-month net loss was $21.3 million ($0.94/share) vs. $25.7 million ($1.72/share) prior year.
• R&D expenses increased to $6.5 million in Q3 2026 (from $5.3 million) driven by NDA activities and commercial readiness; G&A decreased to $1.5 million (from $1.8 million) due to lower non-cash stock-based compensation; marketing expenses were $0.4 million.
• Cash, equivalents, and short-term deposits totaled $15.5 million as of September 30, 2026, excluding a $15 million milestone receivable from Azurity received in early October.
• Management confirms cash resources are sufficient to fund operations into 2028 and cover significant upcoming milestones.

Guidance and Future Outlook:

• FDA PDUFA goal date set for November 28, 2026, for D-Plex 100 (DIPLEX-100) NDA; labeling discussions are underway and on track.
• U.S. commercial launch by partner Azurity targeted for early 2027, pending FDA approval.
• CMS NTAP decision for D-Plex 100 expected in August 2027; if granted, provides up to 75% additional reimbursement above standard DRG payments.
• FDA communications regarding label expansion to broader abdominal surgeries (approx. 4 million procedures/year) planned to initiate in Q4 2026.
• European MAA validation complete; EMA decision expected H2 2027 with potential EU launch in 2028.
• PD-01B (diabetic foot infections) pre-IND meeting and first-in-human study targeted for H2 2027.

Business Segments and Product Lines:

• D-Plex 100 (DIPLEX-100): Primary focus for prevention of surgical site infections in colorectal surgery; partnership with Azurity includes $30 million received plus $290 million in potential milestones.
• D-Plex 100 Expansion: Strategic shift to broader abdominal indications (GI, hysterectomies) and soft tissue/bone surgery; clinical development for new indications funded by Azurity upon joint prioritization.
• PD-01B: Novel kinetic for moderate-to-severe diabetic foot infections using localized hyper-doxycycline; builds on D-Plex manufacturing platform with global commercial rights held by PolyPID.
• PD-03A: Long-acting obesity program remains in early preclinical development.
• European Strategy: Rights to D-Plex 100 in Europe reverted to PolyPID following termination of 2022 agreement with Advanced Pharma; active partner selection ongoing.

Market and Competitive Landscape:

• Target Market: Initial focus on colorectal surgery (approx. 2 million procedures in US) expanding to 4 million annual abdominal procedures; competition driven by need for infection reduction in open procedures where infection rates are higher.
• Partner Capabilities: Azurity brings 200+ commercial staff, access to 1,700+ hospitals, and existing relationships with infectious disease specialists and bowel prep product lines.
• Adoption Dynamics: Market research indicates 90% pharmacist willingness to adopt without NTAP, rising to 100% with NTAP; adoption driven by competitive pressure among academic centers to adopt superior technology.
• Economic Value: Product reduces infection rates by 60% and lowers infection complexity; data supports reduction in length of stay and discharge timing.

Risks and Challenges:

• Regulatory Uncertainty: FDA approval decision pending; potential label conditions or deficiencies could delay launch.
• Market Adoption: Ramp-up may be sequential and account-by-account due to varying hospital P&T committee schedules and formulary processes.
• Clinical Trial Requirements: While formal efficacy pilot studies are not expected, some hospitals may require small usability trials (7-10 patients) to verify workflow integration.
• Label Expansion: Parallel vs. sequential expansion into new surgical areas remains dependent on FDA feedback and market adoption signals.

Management Commentary and Tone:

• Tone is highly confident and optimistic, describing the PDUFA date as a "defining moment" and emphasizing a strong balance sheet and clear growth levers.
• Management expressed clarity on the "PolyPID 2030" vision centered on D-Plex 100 maximization, geographic expansion, and pipeline growth.
• Confirmed that all FDA interactions are on track and pre-approval manufacturing inspections are either completed or aligned with milestones.

Analyst Questions and Answers:

• Labeling & FDA: Confirmed labeling discussions are active; specific label details not disclosed pre-approval. FDA is expected to provide feedback on abdominal expansion requirements soon.
• Pre-Approval Inspection: Confirmed standard pre-approval inspections occurred; no specific compliance issues (e.g., Form 483) were disclosed, but management declined to comment on specific status.
• Pricing & Milestones: Azurity will disclose pricing at launch; $290 million in potential milestones exists but breakdown not disclosed; cash recognition depends on specific milestone triggers.
• Adoption Ramp: Launch is a multi-month process starting with MSL engagement and P&T reviews; NTAP approval expected to take effect shortly after launch to facilitate formulary inclusion.
• Economic Data: Existing clinical data (infection reduction, LOS, complexity) deemed sufficient for P&T economic cases; potential for small usability pilots rather than efficacy trials.

Other Key Points:

• Termination of 2022 European agreement with Advanced Pharma allows PolyPID full control over EU commercialization strategy.
• New drug submission for Canada planned for 2027 under the Azurity collaboration framework.
• Microbiology data presented at ID Week 2026 showed 2,185 patients; infections occurring despite prevention maintained reduced complexity.
• PolyPID holds worldwide commercial rights for PD-01B, distinct from the D-Plex 100 licensing model.